Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage

Mohamad Bassam Sonbol, Vishal Rana, S. Sirop Kenderian, Heidi Finnes, Thomas E. Witzig

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

Liver dysfunction in patients with lymphoma presents an important clinical dilemma because it limits the use of anthracyclines and vinca alkaloids for this potentially curable malignancy. Patients are typically treated with corticosteroids, rituximab and the nitrogen mustard mechlorethamine, and then transitioned to definitive therapy after improvement in liver function. Between 2010 and 2012 mechlorethamine was not available and other strategies were required. In this case series, we describe seven cases of patients with lymphoma and liver dysfunction successfully treated in this time period with ifosfamide/carboplatin or gemcitabine/cisplatin.

Original languageEnglish (US)
Pages (from-to)1815-1821
Number of pages7
JournalLeukemia and Lymphoma
Volume55
Issue number8
DOIs
StatePublished - Aug 2014

Keywords

  • Hodgkin lymphoma
  • Liver disease
  • Nitrogen mustard
  • Non-Hodgkin lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Therapeutic options for patients with lymphoma and liver dysfunction or failure during mechlorethamine shortage'. Together they form a unique fingerprint.

  • Cite this